Company intelligence / Profile preview

Demeetra AgBio

Lexington, Kentucky, United Statesdemeetra.com ↗

Ownership: Private
Employees: ~32
Development stage: Preclinical

Overview

Demeetra has demonstrated robust gene-editing capabilities in mammalian cells, yeast, and plants using Cas-CLOVER. Their engineered CHO cell lines show high productivity for biosimilar production. They are also developing plant-based systems for cannabinoid production with high yield and purity but have not reported clinical results or active human trials to date

Therapeutic areas: OtherNeurology
Modalities: Gene editing technologies (Cas-CLOVER, piggyBac transposase)
Industry: Non-Drug Biotech

Partnerships

Notable partnerships include licensing agreements with Hera BioLabs and Poseida Therapeutics (for related but distinct fields), as well as outlicensing to top pharmaceutical, biotech, and agtech companies. Specific partner names are not disclosed publicly.

Beyond the preview

Go deeper on Demeetra AgBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Demeetra AgBio.

Explore the full profile